Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Zu-cheng Xie"'
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 3812-3829 (2023)
Abstract Background Diffuse large B‐cell lymphoma (DLBCL) is a non‐Hodgkin lymphoma with high mortality rates. Small nucleolar RNAs (snoRNAs) are tumor‐specific biological markers, but there are few studies on the role of snoRNAs in DLBCL. Mate
Externí odkaz:
https://doaj.org/article/ebd1c938154146b28dbf3f4be989553b
Publikováno v:
Cancer Medicine, Vol 8, Iss 18, Pp 7623-7636 (2019)
Abstract Background Increasing evidence has validated the crucial role of alternative splicing (AS) in tumors. However, comprehensive investigations on the entirety of AS and their clinical value in glioblastoma (GBM) are lacking. Methods The AS prof
Externí odkaz:
https://doaj.org/article/69af00107e534884881f9a79ee76dd29
Autor:
Xia Yang, Wen-ting Huang, Rong-quan He, Jie Ma, Peng Lin, Zu-cheng Xie, Fu-chao Ma, Gang Chen
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-21 (2019)
Abstract Background Surgery, adjuvant chemotherapy, and radiotherapy are the primary treatment options for soft tissue sarcomas (STSs). However, identifying ways to improve the prognosis of patients with STS remains a considerable challenge. Evidence
Externí odkaz:
https://doaj.org/article/5ae3dac3c9fb4f3d9b7b35ae5768238f
Autor:
Yu Zhang, Wen-jie Chen, Ting-qing Gan, Xiu-ling Zhang, Zu-cheng Xie, Zhi-hua Ye, Yun Deng, Ze-feng Wang, Kai-teng Cai, Shi-kang Li, Dian-zhong Luo, Gang Chen
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-18 (2017)
Abstract HOXA11 antisense RNA (HOXA11-AS) has been shown to be involved in tumorigenesis and development of different cancers. However, the role of HOXA11-AS in non-small cell lung cancer (NSCLC) remains unclear. In this study, we firstly explored an
Externí odkaz:
https://doaj.org/article/a9a7e6dbe4514844bfc72a8d6a574a7e
Autor:
Ting-qing Gan, Zu-cheng Xie, Rui-xue Tang, Tong-tong Zhang, Dong-yao Li, Zu-yun Li, Gang Chen
Publikováno v:
Tumor Biology, Vol 39 (2017)
MicroRNAs have been reported to be involved in various biological processes. Here, we performed a systematic analysis to explore the clinical value and potential molecular mechanism of miR-145-5p in non-small cell lung cancer. First, a meta-analysis
Externí odkaz:
https://doaj.org/article/86db386c61d841d89988b931b4b7bc60
Publikováno v:
Cancer Medicine. 12:3812-3829
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bfd580517178ee9dbdd93dd3be933c09
https://doi.org/10.1002/cam4.5115
https://doi.org/10.1002/cam4.5115
Autor:
Zhi-Gang Peng, Rong-Quan He, Li Gao, M W Li, Gang Chen, Tian-tian Li, Jie Ma, Li-Hua Yang, K T Cai, Zu-cheng Xie
Publikováno v:
Neoplasma. 67:623-635
This study aimed to create prognostic signatures to predict AML patients' survival using alternative splicing (AS) events. The AS data, RNA sequencing data, and the survival statistics of 136 AML patients were obtained from The Cancer Genome Atlas (T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a45a255a8854e779928d7cd2826673de
https://doi.org/10.4149/neo_2020_190917n922
https://doi.org/10.4149/neo_2020_190917n922
Publikováno v:
Aging (Albany NY)
Alternative splicing (AS) is crucial a mechanism by which the complexity of mammalian and viral proteom increased overwhelmingly. There lacks systematic and comprehensive analysis of the prognostic significance of AS profiling landscape for uteri cor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a44724f225e43869b47a7b882ac72da2
https://doi.org/10.18632/aging.101753
https://doi.org/10.18632/aging.101753
Publikováno v:
Pathology - Research and Practice. 214:644-654
Background Lung squamous cell cancer (LUSC) is a common but challenging malignancy. It is important to illuminate the molecular mechanism of LUSC. Thus, we aim to explore the molecular mechanism of miR-136-5p in relation to LUSC. Methods We used the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa44a1944fe294e65b43555aca97b6b7
https://doi.org/10.1016/j.prp.2018.03.028
https://doi.org/10.1016/j.prp.2018.03.028
Autor:
Zu-cheng Xie1, Yi-wu Dang1, Dan-ming Wei1, Peng Chen1, Rui-xue Tang1, Qian Huang1, Jiang-hua Liu1,2 13878802796@163.com, Dian-zhong Luo1 ldz2012@126.com
Publikováno v:
OncoTargets & Therapy. Aug2017, Vol. 10, p3991-4005. 15p.